Medifast Reports 34.3% Revenue Decline and $2.1 Million Net Loss in Q1 2026

Medifast, Inc. reported a significant decline in financial performance for the first quarter of 2026, with revenues falling to $76.0 million, a decrease of 34.3% from $115.7 million in the same period of 2025. The company's gross profit also decreased by 38.6%, amounting to $51.8 million, primarily due to lower sales volumes and a decrease in the number of active earning coaches, which dropped to 14,000 from 25,400 year-over-year. The company recorded a net loss of $2.1 million, or $0.19 per share, compared to a net loss of $0.8 million, or $0.07 per share, in the prior year.

The decline in revenue was attributed to ongoing challenges in client acquisition, exacerbated by the rising popularity of GLP-1 medications for weight loss, which have impacted the traditional weight loss market. Despite the decrease in revenue, the average revenue per active earning coach increased to $5,432 from $4,556, indicating a shift towards a more productive coach network. The company's selling, general, and administrative expenses also decreased by 35.6% to $55.1 million, driven by lower coach compensation and marketing expenses, as well as a one-time gain of $2.2 million from the sale of its Maryland Distribution Center.

Operationally, Medifast's strategic focus has shifted towards metabolic health, with plans to launch new product innovations aimed at enhancing metabolic function. The company is leveraging its network of independent coaches, approximately 90% of whom were clients first, to drive client engagement and retention. The coach network is seen as a critical component of Medifast's business model, which emphasizes personalized support and community engagement.

Looking ahead, Medifast anticipates continued challenges in the operating environment, particularly with the ongoing decline in active earning coaches. However, the company remains committed to its transformation strategy, which includes enhancing its product offerings and improving coach productivity. Medifast's management believes that by addressing the root causes of metabolic dysfunction, it can unlock new opportunities and better serve a broader range of clients. The company is also focused on maintaining operational resilience amid macroeconomic uncertainties, including inflation and changing consumer behaviors.